Loading…
← CockpitCompetitor Analysis › ZBIO Zenas BioPharma, Inc.Open in the cockpit ↗

Zenas BioPharma, Inc.ZBIOCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops immunology and oncology antibody therapies, in-licensed from China and developed globally.

Momentum strong 64
Mkt cap
$1.79B
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$13.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.4%
Hurdle
n/a
no reverse DCF
Next earnings
124 days
22 Mar 2027
Close · USD$26.42
1D-4.8%
1W-7.9%
1M-6.2%
3M-16.4%
6M+35.1%
YTD-27.2%
1Y-26.4%
ATR %6.6%
Beta0.75
52w lowhigh40.8% off high

What Zenas BioPharma does

Develops immunology and oncology antibody therapies, in-licensed from China and developed globally.

Has no approved product and is funded by investors rather than sales. It keeps costs down by in-licensing drugs partly developed elsewhere, so it pays milestones and royalties to the originators. Obexelimab, licensed from Xencor, is its lead, aimed at IgG4-related disease, a rare condition that causes organ swelling.

Products and services

  • Obexelimab (IgG4-related disease, autoimmune)
  • Oncology antibody pipeline

Customers

  • Rheumatologists/immunologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Immunology and oncology antibody…

What could go right

  • Pivotal trial data readouts
  • In-licensing additional China-origin assets

What could go wrong

  • Clinical trial failure risk
  • Dependence on Chinese licensing partners

Moat: narrow (IP / patents, regulatory licence). Global development rights to in-licensed China-origin biologics, differentiated but unproven commercially.

Headquarters: Waltham, Massachusetts, US · Founded: 2021 · Employees: 167

Named competitors

Zenas BioPharma at a glance

Size Zenas BioPharma (ZBIO) is a United States Health Care company (Biotechnology) with a market value of $1.79B, the 1847th largest of 3,085 United States companies the cockpit tracks. Shares closed at $26.42 on 18 Nov 2026.

Performance Over six months the shares gained 35.1%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue fell 26.7% over the last twelve months (peer median +16.6%); the operating margin is -2,747.6% (peer median -0.2%).

Valuation It trades at 146.1× enterprise value to sales against a peer median of 10.9× (2nd most expensive of 15).

Credit Zenas BioPharma has 1 bond outstanding ($230M).

Short interest Short interest is 16.7% of the free float (30 Oct 2026).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515017521 May 202621 Aug 202618 Nov 2026ZBIO 133Peer median 91
Six months, rebased to 100: Zenas BioPharma against the median of its 20 peers (local-currency closes).

Zenas BioPharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$11.0M$10.0M$5.00M$50.0M$0
Revenue growth—+100%-90%——
Gross profit$11.0M$9.94M$4.86M$49.9M-$78,000
EBITDA-$302M-$211M-$164M-$27.0M-$75.1M
Net income-$542M-$378M-$157M-$37.1M-$119M
Free cash flow-$243M-$172M-$120M-$30.5M-$65.8M
Capital expenditure$3,000$18,000$131,000$17,000$2.20M
Total debt$400M$80.0M$1.00M$21.1M$1.53M

Quarterly statements and history in the cockpit →

Zenas BioPharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%688046RXRXCOAGSTOKVERA300601TRAXSEPNREPL145020MRVIALVO688222ZBIO6-month return →1-month return →
Up and to the right = strong over both horizons. Zenas BioPharma is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%+300%0×50×100×150×688046RXRXSTOK300601SEPNBCRX145020688520MRVI600226ZBIORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zenas BioPharma is the large dot.

Zenas BioPharma competitors and peer comparison

Head to head with its named competitors (ZBIO vs RO.SW vs AMGN vs ARGX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Zenas BioPharma ZBIO$1.79B+35%-27%-2,748%146.1×n/a
Roche RO.SW$381B+21%-1%31%5.7×1.7%
Amgen AMGN$240B+34%+9%36%7.2×1.6%
argenx SE Sponsored ADR ARGX$59.1B+17%+71%29%10.3×11.7%

How Zenas BioPharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zenas BioPharma against its 20 peers (data as of 18 Nov 2026)
MeasureZBIOPeer medianRank in peer set
1-month return-6.2%-1.6%10th lowest of 20
6-month return+35.1%-4.6%8th highest of 20
Distance from 52-week high-40.8%-33.4%6th lowest of 21
Revenue growth (TTM)-26.7%+16.6%5th lowest of 16
Operating margin-2,747.6%-0.2%2nd lowest of 16
EV / Sales146.1×10.9×2nd most expensive of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%4.2×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%1.7×-7.6%+33.5%
Alvotech ALVOUnited States$1.62B+38%-14%12%6.4×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%14.4×33.2%+16.8%
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a

Zenas BioPharma bonds and credit

Zenas BioPharma has 1 bond outstanding with $230M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Zenas BioPharma's main competitors?
Named competitors: Roche (RO.SW), Amgen (AMGN), Argenx (ARGX). The cockpit's measured peer set (industry) also includes GemPharmatech (688046.SS), Lycia Therapeutics (LYCA), Recursion Pharmaceuticals (RXRX), Hemab Therapeutics (COAG), Stoke Therapeutics (STOK), Vera Therapeutics (VERA).
Is Zenas BioPharma expensive compared with its peers?
On ev / sales it trades at 146.1× against a peer median of 10.9×, 2nd most expensive of 15 in its peer set.
How has Zenas BioPharma stock performed?
Over six months to 18 Nov 2026 the shares returned +35.1% against -4.6% for the median peer; over one year -26.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.